Notice of AGM and Report and Accounts

RNS Number : 6244T

Avacta Group PLC

08 December 2011

 



Press release

8 December 2011

Avacta Group plc

("Avacta" or "the Group")

Notice of AGM and Report and Accounts

Avacta Group plc (AIM:AVCT), a leading provider of proprietary analytical and diagnostic technology, consumables and reagents, to the drug development and healthcare sectors, today announces that copies of the Annual Report and Accounts for the year ended 31 July 2011 have been sent to shareholders along with the Notice of Annual General Meeting ("AGM"). Copies of both documents are also available from the Company's website, www.avacta.com.

The AGM will be held at the offices of Walker Morris, Kings Court, 12 King Street, Leeds, LS1 2HL on Monday 23 January 2012 at 2.00pm.

-Ends-

For further information please contact:

Avacta Group plc Alastair Smith, Chief Executive Officer Tim Sykes, Chief Financial Officer	Tel:  [phone] www.avacta.com
Nominated Adviser and Broker Panmure Gordon (UK) Limited Aubrey Powell/Andrew Burnett/Charles Leigh-Pemberton (Broking)	Tel: [phone]
Media Enquiries Abchurch Communications Sarah Hollins/Adam Michael/Oliver Hibberd [e-mail]	Tel: [phone] www.abchurch-group.com

Notes to editors:

Avacta Group plc is a leading provider of proprietary analytical and diagnostic technology, consumables and reagents, to the drug development and healthcare sectors through two operating divisions:

Avacta Analytical provides high-end analytical instrumentation, consumables and services to the biopharmaceutical sector, expected to be a US$200 billion market by 2013 and the fastest growing part of the pharmaceutical industry. The Group's technologies are aimed at reducing the risks and expense associated with biological drug development and thereby reducing the final cost of drugs to patients. The Group's lead analytical instrument, Optim, is distributed through Pall Corporation in the US and South East Asia, Isogen Life Sciences in Europe, Cold Spring Biotech Corp in China and Taiwan and DKSH in Japan. Avacta sells Optim directly in the UK.

Avacta Animal Health provides diagnostic products, reagents and services for the US$1.5 billion global veterinary diagnostics market. Its aim is to equip veterinary professionals with high quality animal health and well-being information, through point of care diagnostics, reagents and testing kits and laboratory based testing. Avacta's AX-1 point of care immunoassay system is aimed at providing the veterinarian with rapid blood test results in the clinic. The initial range of tests launched with the AX-1 relates to Avacta's world leading allergy testing brand Sensitest®. Avacta is currently developing further assays for the AX-1 system to diagnose other diseases in companion animals. Longer term this technology will be transferred into the human clinical diagnostics market.

Avacta joined AIM in August 2006 and is based in Wetherby, England.

 

END

 

 

MSCFSUFLAFFSEFE